BioAlliance Pharma SA (Paris:BIO) (Euronext Paris - BIO), a company dedicated to specialty and orphan oncology products today announces, following its Shareholders’ meeting of June 29, 2011, the launch of a capital increase for an amount of approximately 16 million Euros with maintenance of preferential subscription rights.
The appointments of Judith Greciet, Patrick Langlois, the company Financière de la Montagne represented by Nicolas Trebouta and David Solomon as Board members have been adopted as expected by the Shareholders’ meeting. The Board of Directors has appointed Judith Greciet as Chief Executive Officer and Patrick Langlois as non-executive President of the Board. This new team, together with the Board members, will commit to providing BioAlliance with a dynamics of growth.
“BioAlliance can transform a concept into a high value asset. The Company has thus created two structured portfolios - “Specialty products” and “Orphan oncology products” - with independent risks, which are the two pillars of its current and future revenues,” declares Judith Greciet, Chief Executive Officer of BioAlliance Pharma. “With BioAlliance team, I wish to speed up the development of our most promising products and to consider the best opportunities for external growth. Optimization of our current and future distribution channels also constitutes a key element to BioAlliance.”
This capital increase with maintenance of preferential subscription rights will enable BioAlliance Pharma:
- To conduct the development program of Livatag® in the treatment of primary liver cancer, in the wake of the significant survival data observed in the phase II trial (17-month increase in the median overall survival as compared to that of chemoembolization). Peak sales of such product can be evaluated between 800 million and 1 billion Euros.
- To complement its orphan products portfolio, in addition to the 3 products already in clinical phase, in order to maximize market access opportunities while benefiting from the Company’s know-how in product development.
In the middle term, BioAlliance Pharma will consider strategic options for commercialization and could contemplate direct commercialization of orphan products in some territories. The company thus intends to optimize its revenues on these very high potential products, while being more independent from partners.
Public information:
All guidelines on how to subscribe are available on the internet on this site: www.bioalliancepharma.com
The prospectus comprises the reference document N° D11-0251 submitted on 7th April 2011, and the offering notice number 11-280 dated 30th June 2011 as approved by the French financial market regulator the AMF. The prospectus can be viewed free of charge at the company’s head office, on BioAlliance Pharma’s website (www.bioalliancepharma.com) and on the AMF website (www.amf-france.org).
BioAlliance Pharma would like to draw investors’ attention to the section in the prospectus approved by AMF that relates to risk factors.
About BioAlliance Pharma
Dedicated to cancer and supportive care treatment with a focus on resistance targeting and orphan products -- BioAlliance conceives and develops innovative products, for specialty markets especially in the hospital setting and for orphan or rare diseases.
Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma’s ambition is to become a leading player in these fields by coupling innovation to patient needs. The company’s teams have the key competencies required to identify, develop and register drugs in Europe and the USA; the products’ commercialization rights are licensed to international commercial partners invested in the hospital setting. In areas where medical needs are insufficiently met, its targeted approaches help overcome drug resistance and improve patient health & quality of life.
BioAlliance Pharma has developed an advanced product portfolio: Specialty products
Loramyc®/Oravig® (oropharyngeal candidiasis in immunocompromised patients): Registered in 28 countries (EU US, Korea)
Sitavir® (Acyclovir Lauriad TM) (labialis herpes): Positive phase III final results; registration status
Fentanyl LauriadTM (chronic cancer pain): Positive preliminary Phase I results
Orphan Oncology products
Livatag® (Doxorubicin Transdrug?) in primary liver cancer: Phase II positive results
Clonidine LauriadTM (mucositis): Phase II on going
AMEP® (invasive melanoma): Phase I on going
For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com
